

CDC

# Monthly, Facility-Based HIV Care/ART Reporting Form

Month: MAY	Year: 2005
Grantee: IHV NIGERIA	Facility:
Location:	Country: NIGERIA

1. HIV care (non-ART and ART) - new and cumulative number of persons enrolled			
	Cumulative number ever enrolled at beginning of month	New enrollees during the month	Cumulative number ever enrolled at end of month (Columns 1 + 2)
1. Males (0-14 years)	13	44	57
2. Males (>14years)	888	345	1233
3. Non-pregnant females (0-14 years)	3	49	52
4. Non-pregnant females (>14 years)	1177	537	1714
5. Pregnant females (0-14 years)	0	0	0
6. Pregnant females (>14 years)	53	7	60
Total	2134	982	3116

2. ART care - new and cumulative number of persons started				
	Cumulative number ever started on ART at the beginning of month	Number started on ART* during the month	Cumulative number ever started on ART at the end of the month (Column 1 + 2)	Number transferring ART care from non-USG program
1. Males (0-14 years)	0	39	39	3
2. Males (>14years)	256	114	370	183
3. Non-pregnant females (0-14 years)	0	38	38	7
4. Non-pregnant females (>14 years)	290	183	473	272
5. Pregnant females (0-14 years)	0	0	0	0
6. Pregnant females (>14 years)	14	4	18	2
Total	560	378	938	467
Total number enrolled and eligible for ART but have not been started on ART		182		
No. of persons on ART and already enrolled in program at another site who transferred into facility in last month		0		
No. of baseline CD4* counts for persons who started ART in the last month		203		
Median baseline CD4* count for persons who started ART in the last month				

\*PEPFAR ART

3. Number of personnel trained in HIV/ART care during the month	Physicians	Nurses	Other staff	Subtotal
1. ART care	86	59	2	147
2. Non-ART HIV care	0	0	0	0
Total personnel trained				147





**Supplementary Information UMD IHVN**

<b>7.1 PMTCT - new and cumulative number of persons enrolled / training</b>			
	Cumulative number ever enrolled at beginning of month	New enrollees during the month	Cumulative number ever enrolled at end of month (Columns 1 + 2)
1. No. of service outlets	5	0	5
2. No. of pregnant women provided services	1162	652	1814
3. No. rec. complete ARV proph	54	25	79

<b>7.2 Number of personnel trained in PMTCT</b>				
	Physicians	Nurses	Other staff	Subtotal
1. PMTCT	19	13	13	45
			Total personnel trained	45

<b>8. Laboratory Trainings</b>		
		Total participants
1. Master Trainers	18 Jan-11 Feb 05	12
2. Good Laboratory Practice	21 Mar - 23 Mar 05	39
3. CyFlow and GLP	14-19 Mar 05	46
4. Lab Inspection and QA	5 April - 15 April	6
Total personnel trained		103

<b>9. M &amp; E Trainings</b>		
		Total participants
1. ART Monitoring Orientation	11-13 April 05	14
Total personnel trained		14

<b>10. Adherence Counseling Trainings</b>		
		Total participants
1. Amino Kano Teaching Hosp.	25 Feb. 2005	9
2. Gwagwalada Spec Hosp	2-Mar-05	7
3. Amino Kano Teaching Hosp.	31-Mar-05	2
Central Adherence Counselor Training	19 April - April 2005	34
Total personnel trained		52

**Notes**

Five of six sites active in May with ARV support. UCTH due to initiate services first week of June.  
Pediatric ARV treatment at five sites in May

Extensive support/development expertise provided for adaptation of National PMTCT Training Curriculum which was piloted 22May - 27 May with a second pilot planned in June  
Prior months PMTCT service data being manually abstracted from ledgers and will be updated.  
Support provided to National PMTCT Task Team. Updated National PMTCT Guidelines were completed in May.

Some delay in obtaining CD4 data due to delay in availability of data management software (to be provided by Futures/FHI). Beta version made available in late May.

Worked with FHI/Axios to address anticipated lack of availability of Zerit. Additional Retrovir ordered by Axios to facilitate adequate availability of first line ARV regimen stock through the Su Nigerian ARV Guideline Committee met in May and accepted recommended IP consensus changes presented by ACTION to facilitate broadening of first line choices and updated 2nd line / 9000+ units of Truvada donated to UMD by Gilead. Will be available to address first line regimen shortfalls in future months.

Have requested a first line adult ARV regimen mix of 25% Zerit, 45% Retrovir, 30% Tenofovir coformulated as Truvada as of Nov.1 as anticipated drug #1 mix for first line adult ARV treatment  
Have requested a 50:50 mix of nevirapine:efavirenz as drug #3 and will utilize 3TC/FTC as drug #2 depending upon availability.

Advised by GHAIN/AXIOS that OI drugs (with the exception of donated Fluconazole) will not arrive in country until July. Will time non-ARV care training to coincide with that arrival.

Extensive on-site laboratory trainings in use of automated Cyflow, Vitrox, and Sysmex took place in May.

Formal trainings at Asokoro site on a variety of topics to recommence in June including a collab w. Safe Blood for Africa targeting blood bankers.

Planning underway for training of staff at TB points of service in rapid HIV testing at Askoro Training Laboratory.

Six referral and three secondary laboratories (Lagos, Calabar, Kano) operational. Delay in full automation at Kano secondary laboratory due to lack of reliable power and delay in availability







immer  
ART regimen recommendations  
ent at ACTION sites

, of laboratory scientists to train